|
US2073403A
(en)
|
1935-11-23 |
1937-03-09 |
Abraham G Goldberg |
Display device
|
|
US4044126A
(en)
|
1972-04-20 |
1977-08-23 |
Allen & Hanburys Limited |
Steroidal aerosol compositions and process for the preparation thereof
|
|
GB1429184A
(en)
|
1972-04-20 |
1976-03-24 |
Allen & Hanburys Ltd |
Physically anti-inflammatory steroids for use in aerosols
|
|
US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US4714681A
(en)
|
1981-07-01 |
1987-12-22 |
The Board Of Reagents, The University Of Texas System Cancer Center |
Quadroma cells and trioma cells and methods for the production of same
|
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US4925648A
(en)
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
EP1541682A3
(en)
|
1988-09-02 |
2005-07-06 |
Dyax Corp. |
Generation and selection of recombinant varied binding proteins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
|
WO1991010737A1
(en)
|
1990-01-11 |
1991-07-25 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
|
US5780225A
(en)
|
1990-01-12 |
1998-07-14 |
Stratagene |
Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
ES2087997T3
(es)
|
1990-01-12 |
1996-08-01 |
Cell Genesys Inc |
Generacion de anticuerpos xenogenicos.
|
|
IT1246382B
(it)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
|
DE69130709T3
(de)
|
1990-10-05 |
2005-12-22 |
Celldex Therapeutics, Inc. |
Gezielte immunostimulierung mit bispezifischen stoffen
|
|
EP0557300B1
(en)
|
1990-10-29 |
1997-11-19 |
Chiron Corporation |
Bispecific antibodies, method of production, and uses thereof
|
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
ATE414768T1
(de)
|
1991-04-10 |
2008-12-15 |
Scripps Research Inst |
Bibliotheken heterodimerer rezeptoren mittels phagemiden
|
|
DE69214709T2
(de)
|
1991-04-26 |
1997-02-20 |
Surface Active Ltd |
Neue Antikörper und Verfahren zu ihrer Verwendung
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
CA2110799A1
(en)
|
1991-06-14 |
1992-12-23 |
Arnold H. Horwitz |
Microbially-produced antibody fragments and their conjugates
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
|
EP1291360A1
(en)
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
EP0627940B1
(en)
|
1992-03-05 |
2003-05-07 |
Board of Regents, The University of Texas System |
Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US6010715A
(en)
|
1992-04-01 |
2000-01-04 |
Bertek, Inc. |
Transdermal patch incorporating a polymer film incorporated with an active agent
|
|
US6024975A
(en)
|
1992-04-08 |
2000-02-15 |
Americare International Diagnostics, Inc. |
Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
EP1498427B1
(en)
|
1992-08-21 |
2009-12-16 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
|
DK0698097T3
(da)
|
1993-04-29 |
2001-10-08 |
Unilever Nv |
Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
|
WO1995015982A2
(en)
|
1993-12-08 |
1995-06-15 |
Genzyme Corporation |
Process for generating specific antibodies
|
|
US5997873A
(en)
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
|
DE69531148T2
(de)
|
1994-01-31 |
2004-04-29 |
Trustees Of Boston University, Boston |
Bibliotheken aus polyklonalen antikörpern
|
|
IL108501A
(en)
|
1994-01-31 |
1998-10-30 |
Mor Research Applic Ltd |
Antibodies and pharmaceutical compositions containing them
|
|
US5516637A
(en)
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5983134A
(en)
|
1995-04-23 |
1999-11-09 |
Electromagnetic Bracing Systems Inc. |
Electrophoretic cuff apparatus drug delivery system
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
|
US6167301A
(en)
|
1995-08-29 |
2000-12-26 |
Flower; Ronald J. |
Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
|
|
US5935576A
(en)
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
|
JP2978435B2
(ja)
|
1996-01-24 |
1999-11-15 |
チッソ株式会社 |
アクリロキシプロピルシランの製造方法
|
|
AU728657B2
(en)
|
1996-03-18 |
2001-01-18 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
|
US6027947A
(en)
|
1996-08-20 |
2000-02-22 |
Ramtron International Corporation |
Partially or completely encapsulated top electrode of a ferroelectric capacitor
|
|
US5985317A
(en)
|
1996-09-06 |
1999-11-16 |
Theratech, Inc. |
Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
|
|
AU722289B2
(en)
|
1996-10-01 |
2000-07-27 |
Aptalis Pharmatech, Inc. |
Taste-masked microcapsule compositions and methods of manufacture
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
EP2305027B1
(en)
|
1996-12-03 |
2014-07-02 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
|
US5860957A
(en)
|
1997-02-07 |
1999-01-19 |
Sarcos, Inc. |
Multipathway electronically-controlled drug delivery system
|
|
US6017540A
(en)
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
|
SI0970126T1
(en)
|
1997-04-14 |
2001-08-31 |
Micromet Ag |
Novel method for the production of antihuman antigen receptors and uses thereof
|
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US5948433A
(en)
|
1997-08-21 |
1999-09-07 |
Bertek, Inc. |
Transdermal patch
|
|
CN1152673C
(zh)
|
1997-10-28 |
2004-06-09 |
坂东化学株式会社 |
皮肤贴附药片及其基片的制造方法
|
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
|
JP5341287B2
(ja)
|
1998-12-03 |
2013-11-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｃｔｌａ−４遮断薬を用いる自己抗原に対するｔ細胞の刺激
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
|
US6256533B1
(en)
|
1999-06-09 |
2001-07-03 |
The Procter & Gamble Company |
Apparatus and method for using an intracutaneous microneedle array
|
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
DK1233987T3
(da)
|
1999-11-29 |
2009-09-28 |
Bac Ip B V |
Immobiliserede enkelt-domæne antigenbindende molekyler
|
|
EP3225632B1
(en)
|
1999-11-30 |
2020-05-06 |
Mayo Foundation for Medical Education and Research |
Antibodies binding to b7-h1, a novel immunoregulatory molecule
|
|
US6261595B1
(en)
|
2000-02-29 |
2001-07-17 |
Zars, Inc. |
Transdermal drug patch with attached pocket for controlled heating device
|
|
DE60143798D1
(de)
|
2000-06-16 |
2011-02-17 |
Cambridge Antibody Tech |
Immunspezifisch bindende antikörper gegen blys
|
|
AU2001276842B2
(en)
|
2000-06-28 |
2007-04-26 |
Glycofi, Inc. |
Methods for producing modified glycoproteins
|
|
CA2424977C
(en)
|
2000-10-06 |
2008-03-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
|
WO2002096948A2
(en)
|
2001-01-29 |
2002-12-05 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
IL149701A0
(en)
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
|
IL166244A0
(en)
|
2001-07-12 |
2006-01-15 |
Jefferson Foote |
Super humanized antibodies
|
|
JP4249013B2
(ja)
|
2001-07-31 |
2009-04-02 |
佑 本庶 |
Ｐｄ−１に対し特異性を有する物質
|
|
RU2321630C2
(ru)
|
2001-08-03 |
2008-04-10 |
Гликарт Биотекнолоджи АГ |
Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
AUPS054702A0
(en)
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
CA2799805C
(en)
|
2002-03-19 |
2016-05-17 |
Stichting Dienst Landbouwkundig Onderzoek |
Optimizing glycan processing in plants
|
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
EP2206517B1
(en)
|
2002-07-03 |
2023-08-02 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions comprising anti-PD-L1 antibodies
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
PL222222B1
(pl)
|
2003-01-22 |
2016-07-29 |
Glycart Biotechnology Ag |
Sposób wytwarzania polipeptydu
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
WO2005035575A2
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
|
AU2005282700A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
WO2006042237A2
(en)
|
2004-10-06 |
2006-04-20 |
Mayo Foundation For Medical Education And Research |
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
WO2007039818A2
(en)
|
2005-05-09 |
2007-04-12 |
Glycart Biotechnology Ag |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
JP2006327937A
(ja)
|
2005-05-23 |
2006-12-07 |
Ritsutoku Kin |
ヒト胚細胞系遺伝子構造を具えたヒト抗体構造及びその誘導フラグメント
|
|
CN104436190A
(zh)
|
2005-06-08 |
2015-03-25 |
达纳-法伯癌症研究院公司 |
通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
ES2351057T3
(es)
|
2005-07-08 |
2011-01-31 |
Pfizer Limited |
Anticuerpos contra madcam.
|
|
MX2008009220A
(es)
|
2006-01-17 |
2008-10-10 |
Biolex Therapeutics Inc |
Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
CN101074264B
(zh)
|
2006-05-17 |
2011-08-17 |
上海抗体药物国家工程研究中心有限公司 |
一种重组抗ctla4单克隆抗体及其制备方法和用途
|
|
US8907065B2
(en)
|
2006-12-15 |
2014-12-09 |
Ablynx N.V. |
Polypeptides that modulate the interaction between cells of the immune system
|
|
CA2673870A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
JP5191537B2
(ja)
|
2007-06-18 |
2013-05-08 |
エム・エス・ディー・オス・ベー・フェー |
ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
|
|
WO2009024531A1
(en)
|
2007-08-17 |
2009-02-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating and diagnosing hematologic malignancies
|
|
MX2010001918A
(es)
|
2007-08-21 |
2010-03-11 |
Amgen Inc |
Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
|
|
CA3128656A1
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
SI2207809T1
(sl)
|
2007-09-26 |
2013-11-29 |
U3 Pharma Gmbh |
Proteini, ki veĹľejo antigen rastnega faktorja, podobnega epidermalnemu rastnemu faktorju, ki veĹľe heparin
|
|
EP2242773B1
(en)
|
2008-02-11 |
2017-06-14 |
Cure Tech Ltd. |
Monoclonal antibodies for tumor treatment
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
WO2010003118A1
(en)
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
|
PL2315756T3
(pl)
|
2008-07-08 |
2015-02-27 |
Incyte Holdings Corp |
1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
RS54233B1
(sr)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
Kompozicije pd-1 antagonista i postupci za njihovu primenu
|
|
AU2009290543B2
(en)
|
2008-09-12 |
2015-09-03 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
BRPI0919377A2
(pt)
|
2008-09-26 |
2016-09-27 |
Dana Farber Cancer Inst Inc |
anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
|
WO2010102278A1
(en)
|
2009-03-06 |
2010-09-10 |
President And Fellows Of Harvard College |
Methods and compositions for the generation and maintenance of regulatory t cells
|
|
WO2010108154A2
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Selective and potent peptide inhibitors of kv1.3
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
CN102134276A
(zh)
|
2010-01-22 |
2011-07-27 |
上海抗体药物国家工程研究中心有限公司 |
一种抗ctla-4嵌合抗体
|
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
|
US20130202623A1
(en)
|
2010-02-16 |
2013-08-08 |
Nicolas Chomont |
Pd-1 modulation and uses thereof for modulating hiv replication
|
|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
CA2830806C
(en)
|
2011-03-31 |
2020-05-12 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
AU2012273182A1
(en)
|
2011-06-21 |
2014-01-16 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
|
JP6240600B2
(ja)
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
EP3939613A1
(en)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
|
US8920075B2
(en)
|
2011-09-01 |
2014-12-30 |
Halo Maritime Defense Systems, Inc. |
Marine barrier and gate
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
CN104736168B
(zh)
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
|
WO2013192550A2
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
|
CN104936982B
(zh)
|
2012-08-03 |
2020-04-24 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
JP6368308B2
(ja)
|
2012-09-07 |
2018-08-01 |
トラスティーズ・オブ・ダートマス・カレッジ |
癌の診断および治療のためのｖｉｓｔａ調節剤
|
|
CA2886433C
(en)
|
2012-10-04 |
2022-01-04 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
US20150273056A1
(en)
|
2012-10-12 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Enhancement of the immune response
|
|
EP2911669B1
(en)
|
2012-10-26 |
2024-04-10 |
The University of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
MX361680B
(es)
|
2012-12-13 |
2018-12-13 |
Aduro Biotech Inc |
Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
CN105008918A
(zh)
|
2013-01-04 |
2015-10-28 |
西托姆克斯治疗公司 |
用于检测生物系统中的蛋白酶活性的组合物和方法
|
|
US20150344577A1
(en)
|
2013-01-11 |
2015-12-03 |
Dingfu Biotarget Co., Ltd |
Agents for treating tumors, use and method thereof
|
|
EP3578200A1
(en)
|
2013-02-22 |
2019-12-11 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
CN105073135A
(zh)
|
2013-02-22 |
2015-11-18 |
库瑞瓦格有限责任公司 |
疫苗接种和抑制pd-1途径的组合
|
|
WO2014144080A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
US10047137B2
(en)
|
2013-04-05 |
2018-08-14 |
Versitech Limited |
Antibodies against novel PD1 isoforms and uses thereof
|
|
KR102243062B1
(ko)
|
2013-05-02 |
2021-04-21 |
아납티스바이오, 아이엔씨. |
예정된 사멸-1에 대한 항체
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
KR20250024106A
(ko)
|
2013-08-22 |
2025-02-18 |
더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 |
암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
|
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
JP6623353B2
(ja)
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗ｐｄ−１抗体並びにその治療及び診断のための使用
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
WO2015061668A1
(en)
|
2013-10-25 |
2015-04-30 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
|
CN104558177B
(zh)
|
2013-10-25 |
2020-02-18 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
|
|
US20150273033A1
(en)
|
2013-11-05 |
2015-10-01 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
US9580504B1
(en)
|
2013-11-07 |
2017-02-28 |
Curetech Ltd. |
Pidilizumab monoclonal antibody therapy following stem cell transplantation
|
|
MX375221B
(es)
|
2013-11-25 |
2025-03-06 |
Famewave Ltd |
Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
|
|
ES2746805T3
(es)
|
2013-12-12 |
2020-03-06 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
CA2932515C
(en)
|
2013-12-20 |
2023-08-01 |
Intervet International B.V. |
Caninized antibodies
|
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
|
JP7060324B2
(ja)
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
|
KR20220062143A
(ko)
|
2014-01-06 |
2022-05-13 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
|
|
EP4079321A1
(en)
|
2014-01-15 |
2022-10-26 |
Kadmon Corporation, LLC |
Immunomodulatory agents
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
ES2716685T3
(es)
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
DK3099717T3
(da)
|
2014-01-31 |
2019-07-01 |
Novartis Ag |
Antistofmolekyler med tim-3 og anvendelser deraf
|
|
MX381141B
(es)
|
2014-02-10 |
2025-03-12 |
Merck Patent Gmbh |
INHIBICIÓN DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGF ß).
|
|
EP3114144A1
(en)
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
CA2944903A1
(en)
|
2014-04-24 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
|
JP2017515859A
(ja)
|
2014-05-15 |
2017-06-15 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
|
|
WO2015181331A1
(en)
|
2014-05-29 |
2015-12-03 |
Medimmune Limited |
Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
|
|
ES2753360T3
(es)
|
2014-05-29 |
2020-04-08 |
Spring Bioscience Corp |
Anticuerpos contra PD-L1 y usos de los mismos
|
|
US10092645B2
(en)
|
2014-06-17 |
2018-10-09 |
Medimmune Limited |
Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
KR102003754B1
(ko)
|
2014-07-03 |
2019-07-25 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
AU2015287969B2
(en)
|
2014-07-07 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer
|
|
JP6986965B2
(ja)
|
2014-07-22 |
2021-12-22 |
アポロミクス インコーポレイテッド |
抗ｐｄ−１抗体
|
|
CN105330740B
(zh)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
|
WO2016015095A1
(en)
|
2014-07-31 |
2016-02-04 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
US9982053B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
SI3179992T1
(sl)
|
2014-08-11 |
2022-09-30 |
Acerta Pharma B.V. |
Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
|
|
MY198017A
(en)
|
2014-08-19 |
2023-07-26 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
|
US20170247455A1
(en)
|
2014-08-22 |
2017-08-31 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
WO2016030350A1
(en)
|
2014-08-29 |
2016-03-03 |
F. Hoffmann-La Roche Ag |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
JP2018500384A
(ja)
|
2014-11-11 |
2018-01-11 |
メディミューン リミテッド |
腫瘍形成を治療するための治療の組合せ
|
|
US10822414B2
(en)
|
2014-11-11 |
2020-11-03 |
Sutro Biopharma, Inc. |
Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
|
|
US20170313775A1
(en)
|
2014-11-13 |
2017-11-02 |
The Johns Hopkins University |
Checkpoint Blockade and Microsatellite Instability
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
JP2018500332A
(ja)
|
2014-12-16 |
2018-01-11 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
中枢神経系新生物における免疫チェックポイント阻害剤の使用
|
|
CA3175979A1
(en)
|
2014-12-22 |
2016-06-30 |
Pd-1 Acquisition Group, Llc |
Anti-pd-1 antibodies
|
|
AR103268A1
(es)
|
2014-12-23 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra tigit
|
|
HK1246180A1
(zh)
|
2014-12-31 |
2018-09-07 |
Celgene Corporation |
使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
|
|
EA201791768A1
(ru)
|
2015-02-06 |
2018-07-31 |
КАДМОН КОРПОРЕЙШН, ЭлЭлСи |
Иммуномодулирующие агенты
|
|
CN112263677A
(zh)
|
2015-02-26 |
2021-01-26 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
|
WO2016149387A1
(en)
|
2015-03-18 |
2016-09-22 |
The Johns Hopkins University |
Androgen deprivation with immune checkpoint blockade delays the development of castration resistant prostate cancer
|
|
WO2016168143A1
(en)
|
2015-04-14 |
2016-10-20 |
Bristol-Myers Squibb Company |
IMMUNOASSAY FOR SOLUBLE PROGRAMMED DEATH-1 (sPD-1) PROTEIN
|
|
US20180318347A1
(en)
|
2015-04-22 |
2018-11-08 |
Agenus Inc. |
Methods for treating cancer
|
|
ES2861352T3
(es)
|
2015-04-28 |
2021-10-06 |
Bristol Myers Squibb Co |
Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1
|
|
JP2018514550A
(ja)
|
2015-04-28 |
2018-06-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
|
|
PH12017502013B1
(en)
|
2015-05-07 |
2022-07-22 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
WO2016183469A1
(en)
|
2015-05-13 |
2016-11-17 |
Robert Kirken |
Anti-ctla-4 blockade
|
|
US20160347836A1
(en)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
|
|
SI3303394T1
(sl)
*
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
CN105061597B
(zh)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
|
IL256080B2
(en)
|
2015-06-17 |
2025-06-01 |
Genentech Inc |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
EP3313883B1
(en)
|
2015-06-23 |
2023-12-06 |
Memorial Sloan Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
DK3858859T3
(da)
|
2015-07-14 |
2025-12-15 |
Bristol Myers Squibb Co |
Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
|
|
CN106699888B
(zh)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
|
HUE055207T2
(hu)
|
2015-07-30 |
2021-11-29 |
Macrogenics Inc |
PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
|
CN114605548A
(zh)
*
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
KR20250021613A
(ko)
|
2015-09-25 |
2025-02-13 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
|
RU2731418C2
(ru)
|
2015-09-28 |
2020-09-02 |
Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. |
Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
|
|
HK1251158A1
(zh)
|
2015-09-29 |
2019-01-25 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
US10981991B2
(en)
|
2015-09-29 |
2021-04-20 |
Shanghai Zhangjiang Biotechnology Co., Ltd. |
PD-1 antibodies and uses thereof
|
|
KR20180068990A
(ko)
|
2015-10-01 |
2018-06-22 |
포텐자 테라퓨틱스, 인코포레이티드 |
항-tigit 항체-결합 단백질 및 이의 사용 방법
|
|
IL257858B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Anti-pd1 antibodies and methods of use
|
|
SG10201912943RA
(en)
|
2015-10-02 |
2020-02-27 |
Symphogen As |
Anti-pd-1 antibodies and compositions
|
|
WO2017079080A1
(en)
|
2015-11-02 |
2017-05-11 |
The Johns Hopkins University |
Method of preventing organ transplant rejections using agonists to the pd-1 checkpoint pathway
|
|
WO2017079303A1
(en)
|
2015-11-02 |
2017-05-11 |
The Cleveland Clinic Foundation |
Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技（上海）有限公司 |
抗pd-1抗体及其治疗用途
|
|
US10858432B2
(en)
|
2015-12-02 |
2020-12-08 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-1 and methods of use thereof
|
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
|
GB201522311D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
|
CN105669864B
(zh)
|
2015-12-23 |
2018-10-16 |
杭州尚健生物技术有限公司 |
抗人程序性死亡受体1抗体及其制备方法和用途
|
|
JP2019509759A
(ja)
|
2016-01-14 |
2019-04-11 |
ビーピーエス バイオサイエンス、インク．Ｂｐｓ Ｂｉｏｓｃｉｅｎｃｅ， Ｉｎｃ． |
抗ｐｄ−１抗体及びその使用
|
|
US10294299B2
(en)
|
2016-01-22 |
2019-05-21 |
MabQuest SA |
Immunological reagents
|
|
KR20180101584A
(ko)
|
2016-01-27 |
2018-09-12 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합을 사용하는 폐암의 치료
|
|
US10918737B2
(en)
|
2016-01-28 |
2021-02-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
KR20180104122A
(ko)
|
2016-01-28 |
2018-09-19 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
면역요법을 향상시키기 위한 히스톤 데아세틸라제 저해제의 용도
|
|
CN105754990A
(zh)
*
|
2016-01-29 |
2016-07-13 |
深圳精准医疗科技有限公司 |
一种pd-1/ctla-4双特异性抗体的制备方法及其应用
|
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
WO2017147368A1
(en)
|
2016-02-24 |
2017-08-31 |
Oncomed Pharmaceuticals, Inc. |
Redirecting immune responses
|
|
WO2017151517A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
US20190086405A1
(en)
|
2016-03-16 |
2019-03-21 |
Bristol-Myers Squibb Company |
Methods of diagnosing and treating lupus
|
|
EP3478792B1
(en)
|
2016-06-30 |
2023-12-13 |
Beckman Coulter, Inc. |
Chemiluminescent substrates
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
US11013802B2
(en)
|
2016-12-07 |
2021-05-25 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|